A5112670620- Lung Cancer Treatments and Mutations
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Research Studies
- Pneumonia and Respiratory Infections
- Colorectal Cancer Treatments and Studies
- Neonatal Respiratory Health Research
- Lung Cancer Diagnosis and Treatment
- Antibiotics Pharmacokinetics and Efficacy
- Medical Imaging and Pathology Studies
- Liver physiology and pathology
- Cancer therapeutics and mechanisms
- Immunotherapy and Immune Responses
- Respiratory and Cough-Related Research
- Antibiotic Resistance in Bacteria
- Inhalation and Respiratory Drug Delivery
- Protease and Inhibitor Mechanisms
- Peptidase Inhibition and Analysis
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Gastric Cancer Management and Outcomes
- Sarcoidosis and Beryllium Toxicity Research
- Congenital Diaphragmatic Hernia Studies
- Immune Cell Function and Interaction
- Chemokine receptors and signaling
- Neuroendocrine Tumor Research Advances
- Virus-based gene therapy research
Tohoku University
2016-2025
Tohoku University Hospital
2005-2023
Furukawa Electric (United Kingdom)
2018
Japan Anti Tuberculosis Association
2014-2018
Tochigi Medical Center
2012-2015
Sendai Medical Center
2014
Japan Clinical Cancer Research Organization
2014
Respiratory Clinical Trials
1991-2013
Japan Association for Development of Community Medicine
2013
Nippon Medical School
2000-2012
Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little known about how its efficacy and safety profile compares that standard chemotherapy.We randomly assigned 230 patients metastatic, non-small-cell who had not previously received chemotherapy receive gefitinib or carboplatin-paclitaxel. The primary end point was progression-free survival; secondary points...
Idiopathic pulmonary fibrosis (IPF) is a fatal disorder without an effective therapy to date. In double-blind, randomized, placebo-controlled trial, 107 patients were prospectively evaluated for efficacy of novel compound, pirfenidone. The difference in the change lowest oxygen saturation by pulse oximetry (SpO2) during 6-minute exercise test, primary endpoint, from baseline 6 months was not significant between two groups (p = 0.0722). prespecified subset who maintained SpO2 greater than 80%...
This study was undertaken to investigate the efficacy and feasibility of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations.The EGFR gene status in various tumor samples obtained from NSCLC examined by DNA sequencing exons 18 23. Patients mutations received (250 mg/d) alone. The response rate, progression-free survival (PFS), toxicity profile were assessed prospectively.Between June 2004...
This multicenter phase II study was undertaken to investigate the efficacy and feasibility of gefitinib for patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations without indication chemotherapy as a result poor performance status (PS).Chemotherapy-naïve PS (patients 20 74 years age Eastern Cooperative Oncology Group 3 4, 75 79 2 >or= 80 1 4) who had EGFR examined by peptide nucleic acid-locked acid polymerase chain reaction...
Section:ChooseTop of pageAbstract <<METHODSRESULTSDISCUSSIONAPPENDIXReferencesCITING ARTICLES
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non-small-cell lung cancer (NSCLC) EGFR mutations; however, little known about efficacy and safety this combination compared that standard therapy EGFR- inhibitors alone.We randomly assigned 345 patients newly diagnosed metastatic NSCLC mutations to gefitinib carboplatin plus pemetrexed or alone. Progression-free survival (PFS), PFS2,...
To elucidate the apparent contradictions in vascular remodeling lungs of patients with idiopathic pulmonary fibrosis, we evaluated alveolar vascularity relation to various degrees fibrosis surgically biopsied usual interstitial pneumonia. Alveolar capillary endothelial cells were intensely immunoreactive CD34 but not von Willebrand factor. Vascular density, that is, relative ratio area total walls, was significantly higher at low grades than control lungs, whereas density gradually decreased...
Inflammatory angiogenesis is a critical process in tumor progression and other diseases. The inflammatory cytokine IL-1beta promotes angiogenesis, growth, metastasis, but its mechanisms remain unclear. We examined the association between IL-1beta-induced cell inflammation. induced neovascularization mouse cornea at rates comparable to those of VEGF. Neutrophil infiltration occurred on day 2. Macrophage days 4 6. anti-Gr-1 Ab-induced depletion infiltrating neutrophils did not affect IL-1beta-...
Abstract Inflammatory conditions are associated with tumor development. IL-1β is a multifunctional and proinflammatory cytokine that affects nearly all types of cells. To investigate the role in growth vivo, we transduced retroviral vector coding human gene into mouse Lewis lung carcinoma (LLC) cells subsequently inoculated transformant (LLC/IL-1β) to syngeneic C57BL/6 mice. Tumors derived from LLC/IL-1β grew faster (240%, day 18, vs null-vector control LLC/neo; p &lt; 0.01) showed more...
Amrubicin, a new anthracycline agent, and topotecan are both active for previously treated small-cell lung cancer (SCLC). No comparative study of these agents has been reported. This randomized phase II was conducted to select amrubicin or future evaluation.Patients with SCLC platinum-containing chemotherapy were randomly assigned receive (40 mg/m(2) on days 1 through 3) (1.0 5). Patients stratified by Eastern Cooperative Oncology Group performance status (0, 1, 2) type relapse (chemotherapy...
Previously, we reported the specific occurrence of neutralizing autoantibodies against granulocyte–macrophage colony–stimulating factor (GM-CSF) in bronchoalveolar lavage fluid from 11 Japanese patients with idiopathic pulmonary alveolar proteinosis (I-PAP). The autoantibody was also detected sera all 5 I-PAP examined. To determine that existence is not limited to patients, examined 24 five countries and showed consistently specifically present such patients. Thus, detection can be used for...
Inhaled granulocyte/macrophage-colony stimulating factor (GM-CSF) is a promising therapy for pulmonary alveolar proteinosis (PAP) but has not been adequately studied.To evaluate safety and efficacy of inhaled GM-CSF in patients with unremitting or progressive PAP.We conducted national, multicenter, self-controlled, phase II trial at nine centers throughout Japan. Patients who had lung biopsy cytology findings diagnostic PAP, an elevated serum antibody level, Pa(O(2)) less than 75 mm Hg...
The combination of hemorrhagic pneumonitis and rapidly progressive glomerulonephritis is a characteristic feature Goodpasture's syndrome (GPS), an autoimmune disease resulting from the interaction pathogenic anti–collagen type IV (C-IV) antibodies with alveolar glomerular basement membranes. Lack suitable animal model for this fatal has hampered both basic understanding its etiology development therapeutic strategies. We now report novel GPS using mice deficient in central regulatory...
Hepatocyte growth factor (HGF) is a humoral mediator of epithelial-mesenchymal interactions, acting on variety epithelial cells as mitogen, motogen, and morphogen. Exogenous HGF acts hepatotrophic renotrophic during experimental injury. To investigate whether has pulmotrophic function, human recombinant was administered to C57BL/6 mice with severe lung injury by bleomycin (BLM). Low dose simultaneous continuous administration (50 μ g/mouse/7 d) BLM (100 mg/mouse/7 repressed fibrotic...
The Nrf2 transcription factor is crucial for regulating the cellular defense against various carcinogens. However, relationship between host and cancer metastasis remains unexplored. To address this issue, we examined susceptibility of Nrf2-deficient mice to pulmonary following implantation mouse Lewis lung carcinoma (3LL) cell line. reproducibly exhibited a higher number metastatic nodules than wild-type did. bone marrow (BM) cancer-bearing contained increased numbers inflammatory cells,...
Multipotent stromal cells (MSCs) ameliorate several types of lung injury. The differentiation MSCs into specific at the injury site has been considered as important process in MSC effect. However, although reduce destruction an elastase-induced emphysema model, is relatively rare, suggesting that does not adequately explain recuperation observed. Humoral factors secreted by may also play role ameliorating emphysema. To confirm this hypothesis, was induced lungs C57BL/6 mice intratracheal...
Pulmonary alveolar microlithiasis is an autosomal recessive disorder in which microliths are formed the space.To identify responsible gene that causes pulmonary microlithiasis.By means of a genomewide single-nucleotide polymorphism analysis using DNA from three patients, we have narrowed region candidate located. From this region, identified has mutations all patients with microlithiasis.We gene, SLC34A2, encodes type IIb sodium phosphate cotransporter and mutated six investigated. SLC34A2...